SGAM
ADMS

Smith Group Asset Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Smith Group Asset Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-65,640
Closed -$1.1M – 525
2015
Q3 		$1.1M Sell
65,640
-10
-0% -$228 0.04% 162
2015
Q2 		$1.72M Buy
65,650
+1,200
+2% +$23.3K 0.06% 154
2015
Q1 		$1.13M Buy
+64,450
New +$1.1M 0.04% 172

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Smith Group Asset Management's ADMS Position: Q4 2015 in Review

Smith Group Asset Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2015, closing a stake of 65,640 shares — an estimated $1.1M sold.

Smith Group Asset Management first reported a position in ADMS in Q1 2015 and held it in 3 quarters. The position peaked at $1.72M in Q2 2015. 93 funds tracked by Wall St. Rank hold ADMS as of Q4 2015.

  • Smith Group Asset Management reported no remaining Adamas Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Smith Group Asset Management sold 65,640 Adamas Pharmaceuticals shares in Q4 2015, an estimated $1.1M.
  • Smith Group Asset Management first reported a position in Adamas Pharmaceuticals in Q1 2015 and held it in 3 quarters.
  • Smith Group Asset Management's Adamas Pharmaceuticals position peaked at $1.72M in Q2 2015.
  • 93 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2015.

Based on Smith Group Asset Management's 13F filing for Q4 2015, filed 3 Feb 2016.